KZR250117P12500
- 11.77
- 0.000.00%
Kezar Life Sciences Newsroom
Wells Fargo Maintains Kezar Life Sciences(KZR.US) With Hold Rating, Cuts Target Price to $9
Express News | Kezar Life Sciences Inc - Enters Into Amendment No. 1 to Rights Agreement
H.C. Wainwright Maintains Kezar Life Sciences(KZR.US) With Hold Rating
HC Wainwright & Co. Reiterates Neutral on Kezar Life Sciencesto Neutral
KEZAR MARKETS ANNOUNCES RETIREMENT OF CEO WHIT CONARY & NAMES STEVE MIELE AS THE NEW CHIEF EXECUTIVE OFFICER
Express News | Kezar Life Sciences Inc: On November 13, Regains Compliance With Nasdaq’s Minimum Bid Price Requirement
Kezar Life Sciences Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo Maintains Kezar Life Sciences(KZR.US) With Hold Rating, Cuts Target Price to $11
Kezar Life Sciences GAAP EPS of -$2.78 Beats by $0.37
TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating
Kezar Life Sciences (KZR) Receives a Buy From TD Cowen
Express News | Kezar Life Sciences Inc : Jefferies Cuts Target Price to $18 From $30
Kezar Life Sciences | 10-Q: Q3 2024 Earnings Report
Kezar Life Sciences | 8-K: Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Press Release: Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Kezar Life Sciences 3Q Loss/Shr $2.78 >KZR
Express News | Kezar Life Sciences Q3 Operating Income USD -21.948 Million
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending